Metrics as of 10/15/2026, 12:53 PM (Berlin time), refresh in progress.
Lipocine Stock
Lipocine Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mahesh V. Patel
- Employees
- 14
- Market cap
- $14 M
- IPO
- 22/10/2013
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for…
Lipocine stock: price history
1D
+4.3%
1W
-23.2%
1M
-23.9%
6M
-34.0%
YTD
-79.0%
1Y
-47.4%
2Y
-66.9%
5Y
-91.2%
10Y
-97.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~10% weaker price swings than usual
Ask the agents about Lipocine
Analyst assessment of Lipocine
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
7
BUY
2
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 21/09/2026
Lipocine stock metrics
P/E
-0.9
P/B
0.64
EV/EBITDA
-0.76
RETURN ON EQUITY
-12.0%
NET MARGIN
-1,379.6%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.0%
FLOAT SHARES
7,833,447
AVG. DAILY VOLUME (30D)
3,727,021
Insider transactions (SEC)
Higuchi John W.
Higuchi John W.
Higuchi John W.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Lipocine stock
What does Lipocine do?
Lipocine Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mahesh V. Patel, the company employs around 14 people.
The IPO was on 22/10/2013; the stock trades on NASDAQ under the ticker LPCN.
What do analysts say about Lipocine stock?
9 analysts rate the stock, the consensus is Buy (as of 21/09/2026).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Lipocine report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does Lipocine pay a dividend?
No, Lipocine currently does not pay a dividend.
Which stocks are comparable to Lipocine?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lipocine stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lipocine against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.